Amneal Pharmaceuticals
AMRX
140 hedge funds and large institutions have $394M invested in Amneal Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 49 reducing their positions, and 16 closing their positions.
129% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $581K
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
1% more funds holding
Funds holding: 139 → 140 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.24% less ownership
Funds ownership: 69.03% → 68.79% (-0.24%)
19% less capital invested
Capital invested by funds: $484M → $394M (-$90.2M)
20% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$7.57M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.07M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$2.19M |
| 4 |
MSL
Mackay Shields LLC
New York
|
+$997K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$985K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$5.02M |
| 2 |
SGH
Sivik Global Healthcare
Greenwich,
Connecticut
|
-$2.86M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.68M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2M |
| 5 |
BlackRock
New York
|
-$1.54M |
AMRX Hedge Fund Activity: Q3 2020 in Review
140 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2020, worth a combined $394M — down 19% from $484M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AMRX positions and 16 closed out — a net gain of 2 holders — while 39 added to existing stakes and 49 trimmed.
The largest buyer was Eversept Partners, adding an estimated $7.57M. The largest seller was Arrowstreet Capital, cutting an estimated $5.02M.
- 140 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2020, up from 139 in Q2 2020.
- Funds reported $394M of Amneal Pharmaceuticals stock for Q3 2020, down 19% quarter-over-quarter.
- 18 funds opened new Amneal Pharmaceuticals positions in Q3 2020 and 16 closed out, a net change of +2 holders.
- The largest Amneal Pharmaceuticals buyer in Q3 2020 was Eversept Partners, an estimated $7.57M added.
- The largest Amneal Pharmaceuticals seller in Q3 2020 was Arrowstreet Capital, an estimated $5.02M sold.
Based on aggregated 13F filings for Q3 2020.